A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia

Hae Young Lee, Seok Yeon Kim, Kee Joon Choi, Byung Su Yoo, Dong Hun Cha, Hae Ok Jung, Dong Ryeol Ryu, Joon Hyouk Choi, Kwang Je Lee, Tae Ho Park, Ju Hyeon Oh, Sang Min Kim, Ji Yong Choi, Kye Hun Kim, Jaemin Shim, Woo Shik Kim, Si Wan Choi, Dae Gyun Park, Pil Sang Song, Taek Jong Hong & 3 others Moo Yong Rhee, Seung-Woon Rha, Seung Woo Park

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose The objective of this study was to evaluate the efficacy and tolerability of a triple combination of amlodipine/losartan/rosuvastatin in patients with hypertension and hypercholesterolemia. Methods A randomized, multicenter, double-blind, placebo-controlled study was conducted. Eligible patients with hypertension and a sitting diastolic blood pressure (SiDBP) of >90 mm Hg and LDL-C levels <250 mg/dL were screened. After a 4-week run-in period with therapeutic lifestyle changes and losartan potassium 100 mg once daily, patients who met both blood pressure criteria (80 mm Hg ≤ SiDBP < 110 mm Hg) and the LDL-C level criteria (defined in the National Cholesterol Education Program Adult Treatment Panel III cardiovascular risk categories) were randomized to 1 of 3 groups and treated once daily for 8 weeks: losartan potassium 100 mg + rosuvastatin 20 mg treatment (L/R 100/20) group, amlodipine camsylate 5 mg + losartan potassium 100 mg treatment (A/L 5/100) group, and amlodipine 5 mg + losartan potassium 100 mg + rosuvastatin 20 mg (A/L/R 5/100/20) group. The primary efficacy variables were the percent change in LDL-C in the A/L/R 5/100/20 and A/L 5/100 groups and the mean change of SiDBP in the A/L/R 5/100/20 and L/R 100/20 groups after 8 weeks of treatment, relative to baseline values. Findings A total of 146 patients were enrolled and the demographic characteristics were similar among the 3 treatment groups. After 8 weeks of treatment, the mean (SD) percent change in LDL-C was significantly greater in the A/L/R group than in the A/L group (–48.40% [2.77%] vs –6.70% [3.00%]; P < 0.0001). Moreover, the mean change in SiDBP was significantly greater in the A/L/R group than in the L/R group (–9.75 [0.92] mm Hg vs –1.73 [1.03] mm Hg; P < 0.0001). SiDBP and LDL-C reductions in the A/L/R group were comparable to reductions in the A/L and L/R groups, respectively. Ten adverse events were reported in 7 patients (4.83%), and 1 patient from the A/L group (0.69%) experienced 2 adverse drug reactions (tachycardia and face edema), which were mild and resolved without specific treatment. There were no clinically significant tolerability issues during the treatment period. Implications Triple combination therapy with amlodipine/losartan/rosuvastatin can be an effective therapeutic strategy in patients with hypertension combined with dyslipidemia. These findings will form the foundation of the future development of a single-pill triple combination. ClinicalTrials.gov identifier: NCT02899455.

Original languageEnglish
Pages (from-to)2366-2379
Number of pages14
JournalClinical Therapeutics
Volume39
Issue number12
DOIs
Publication statusPublished - 2017 Dec 1

Fingerprint

Amlodipine
Losartan
Hyperlipidemias
Placebos
Blood Pressure
Therapeutics
Hypertension
Rosuvastatin Calcium
Essential Hypertension
Dyslipidemias
Hypercholesterolemia
Drug-Related Side Effects and Adverse Reactions
Tachycardia
Life Style
Edema
Cholesterol
Demography

Keywords

  • angiotensin receptor blocker
  • calcium channel blocker
  • HMG-CoA reductase inhibitor
  • hypercholesterolemia
  • hypertension

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia. / Lee, Hae Young; Kim, Seok Yeon; Choi, Kee Joon; Yoo, Byung Su; Cha, Dong Hun; Jung, Hae Ok; Ryu, Dong Ryeol; Choi, Joon Hyouk; Lee, Kwang Je; Park, Tae Ho; Oh, Ju Hyeon; Kim, Sang Min; Choi, Ji Yong; Kim, Kye Hun; Shim, Jaemin; Kim, Woo Shik; Choi, Si Wan; Park, Dae Gyun; Song, Pil Sang; Hong, Taek Jong; Rhee, Moo Yong; Rha, Seung-Woon; Park, Seung Woo.

In: Clinical Therapeutics, Vol. 39, No. 12, 01.12.2017, p. 2366-2379.

Research output: Contribution to journalArticle

Lee, HY, Kim, SY, Choi, KJ, Yoo, BS, Cha, DH, Jung, HO, Ryu, DR, Choi, JH, Lee, KJ, Park, TH, Oh, JH, Kim, SM, Choi, JY, Kim, KH, Shim, J, Kim, WS, Choi, SW, Park, DG, Song, PS, Hong, TJ, Rhee, MY, Rha, S-W & Park, SW 2017, 'A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia', Clinical Therapeutics, vol. 39, no. 12, pp. 2366-2379. https://doi.org/10.1016/j.clinthera.2017.10.013
Lee, Hae Young ; Kim, Seok Yeon ; Choi, Kee Joon ; Yoo, Byung Su ; Cha, Dong Hun ; Jung, Hae Ok ; Ryu, Dong Ryeol ; Choi, Joon Hyouk ; Lee, Kwang Je ; Park, Tae Ho ; Oh, Ju Hyeon ; Kim, Sang Min ; Choi, Ji Yong ; Kim, Kye Hun ; Shim, Jaemin ; Kim, Woo Shik ; Choi, Si Wan ; Park, Dae Gyun ; Song, Pil Sang ; Hong, Taek Jong ; Rhee, Moo Yong ; Rha, Seung-Woon ; Park, Seung Woo. / A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia. In: Clinical Therapeutics. 2017 ; Vol. 39, No. 12. pp. 2366-2379.
@article{240c8ccb55d34361aab822fbf9ab26cd,
title = "A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia",
abstract = "Purpose The objective of this study was to evaluate the efficacy and tolerability of a triple combination of amlodipine/losartan/rosuvastatin in patients with hypertension and hypercholesterolemia. Methods A randomized, multicenter, double-blind, placebo-controlled study was conducted. Eligible patients with hypertension and a sitting diastolic blood pressure (SiDBP) of >90 mm Hg and LDL-C levels <250 mg/dL were screened. After a 4-week run-in period with therapeutic lifestyle changes and losartan potassium 100 mg once daily, patients who met both blood pressure criteria (80 mm Hg ≤ SiDBP < 110 mm Hg) and the LDL-C level criteria (defined in the National Cholesterol Education Program Adult Treatment Panel III cardiovascular risk categories) were randomized to 1 of 3 groups and treated once daily for 8 weeks: losartan potassium 100 mg + rosuvastatin 20 mg treatment (L/R 100/20) group, amlodipine camsylate 5 mg + losartan potassium 100 mg treatment (A/L 5/100) group, and amlodipine 5 mg + losartan potassium 100 mg + rosuvastatin 20 mg (A/L/R 5/100/20) group. The primary efficacy variables were the percent change in LDL-C in the A/L/R 5/100/20 and A/L 5/100 groups and the mean change of SiDBP in the A/L/R 5/100/20 and L/R 100/20 groups after 8 weeks of treatment, relative to baseline values. Findings A total of 146 patients were enrolled and the demographic characteristics were similar among the 3 treatment groups. After 8 weeks of treatment, the mean (SD) percent change in LDL-C was significantly greater in the A/L/R group than in the A/L group (–48.40{\%} [2.77{\%}] vs –6.70{\%} [3.00{\%}]; P < 0.0001). Moreover, the mean change in SiDBP was significantly greater in the A/L/R group than in the L/R group (–9.75 [0.92] mm Hg vs –1.73 [1.03] mm Hg; P < 0.0001). SiDBP and LDL-C reductions in the A/L/R group were comparable to reductions in the A/L and L/R groups, respectively. Ten adverse events were reported in 7 patients (4.83{\%}), and 1 patient from the A/L group (0.69{\%}) experienced 2 adverse drug reactions (tachycardia and face edema), which were mild and resolved without specific treatment. There were no clinically significant tolerability issues during the treatment period. Implications Triple combination therapy with amlodipine/losartan/rosuvastatin can be an effective therapeutic strategy in patients with hypertension combined with dyslipidemia. These findings will form the foundation of the future development of a single-pill triple combination. ClinicalTrials.gov identifier: NCT02899455.",
keywords = "angiotensin receptor blocker, calcium channel blocker, HMG-CoA reductase inhibitor, hypercholesterolemia, hypertension",
author = "Lee, {Hae Young} and Kim, {Seok Yeon} and Choi, {Kee Joon} and Yoo, {Byung Su} and Cha, {Dong Hun} and Jung, {Hae Ok} and Ryu, {Dong Ryeol} and Choi, {Joon Hyouk} and Lee, {Kwang Je} and Park, {Tae Ho} and Oh, {Ju Hyeon} and Kim, {Sang Min} and Choi, {Ji Yong} and Kim, {Kye Hun} and Jaemin Shim and Kim, {Woo Shik} and Choi, {Si Wan} and Park, {Dae Gyun} and Song, {Pil Sang} and Hong, {Taek Jong} and Rhee, {Moo Yong} and Seung-Woon Rha and Park, {Seung Woo}",
year = "2017",
month = "12",
day = "1",
doi = "10.1016/j.clinthera.2017.10.013",
language = "English",
volume = "39",
pages = "2366--2379",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "12",

}

TY - JOUR

T1 - A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia

AU - Lee, Hae Young

AU - Kim, Seok Yeon

AU - Choi, Kee Joon

AU - Yoo, Byung Su

AU - Cha, Dong Hun

AU - Jung, Hae Ok

AU - Ryu, Dong Ryeol

AU - Choi, Joon Hyouk

AU - Lee, Kwang Je

AU - Park, Tae Ho

AU - Oh, Ju Hyeon

AU - Kim, Sang Min

AU - Choi, Ji Yong

AU - Kim, Kye Hun

AU - Shim, Jaemin

AU - Kim, Woo Shik

AU - Choi, Si Wan

AU - Park, Dae Gyun

AU - Song, Pil Sang

AU - Hong, Taek Jong

AU - Rhee, Moo Yong

AU - Rha, Seung-Woon

AU - Park, Seung Woo

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Purpose The objective of this study was to evaluate the efficacy and tolerability of a triple combination of amlodipine/losartan/rosuvastatin in patients with hypertension and hypercholesterolemia. Methods A randomized, multicenter, double-blind, placebo-controlled study was conducted. Eligible patients with hypertension and a sitting diastolic blood pressure (SiDBP) of >90 mm Hg and LDL-C levels <250 mg/dL were screened. After a 4-week run-in period with therapeutic lifestyle changes and losartan potassium 100 mg once daily, patients who met both blood pressure criteria (80 mm Hg ≤ SiDBP < 110 mm Hg) and the LDL-C level criteria (defined in the National Cholesterol Education Program Adult Treatment Panel III cardiovascular risk categories) were randomized to 1 of 3 groups and treated once daily for 8 weeks: losartan potassium 100 mg + rosuvastatin 20 mg treatment (L/R 100/20) group, amlodipine camsylate 5 mg + losartan potassium 100 mg treatment (A/L 5/100) group, and amlodipine 5 mg + losartan potassium 100 mg + rosuvastatin 20 mg (A/L/R 5/100/20) group. The primary efficacy variables were the percent change in LDL-C in the A/L/R 5/100/20 and A/L 5/100 groups and the mean change of SiDBP in the A/L/R 5/100/20 and L/R 100/20 groups after 8 weeks of treatment, relative to baseline values. Findings A total of 146 patients were enrolled and the demographic characteristics were similar among the 3 treatment groups. After 8 weeks of treatment, the mean (SD) percent change in LDL-C was significantly greater in the A/L/R group than in the A/L group (–48.40% [2.77%] vs –6.70% [3.00%]; P < 0.0001). Moreover, the mean change in SiDBP was significantly greater in the A/L/R group than in the L/R group (–9.75 [0.92] mm Hg vs –1.73 [1.03] mm Hg; P < 0.0001). SiDBP and LDL-C reductions in the A/L/R group were comparable to reductions in the A/L and L/R groups, respectively. Ten adverse events were reported in 7 patients (4.83%), and 1 patient from the A/L group (0.69%) experienced 2 adverse drug reactions (tachycardia and face edema), which were mild and resolved without specific treatment. There were no clinically significant tolerability issues during the treatment period. Implications Triple combination therapy with amlodipine/losartan/rosuvastatin can be an effective therapeutic strategy in patients with hypertension combined with dyslipidemia. These findings will form the foundation of the future development of a single-pill triple combination. ClinicalTrials.gov identifier: NCT02899455.

AB - Purpose The objective of this study was to evaluate the efficacy and tolerability of a triple combination of amlodipine/losartan/rosuvastatin in patients with hypertension and hypercholesterolemia. Methods A randomized, multicenter, double-blind, placebo-controlled study was conducted. Eligible patients with hypertension and a sitting diastolic blood pressure (SiDBP) of >90 mm Hg and LDL-C levels <250 mg/dL were screened. After a 4-week run-in period with therapeutic lifestyle changes and losartan potassium 100 mg once daily, patients who met both blood pressure criteria (80 mm Hg ≤ SiDBP < 110 mm Hg) and the LDL-C level criteria (defined in the National Cholesterol Education Program Adult Treatment Panel III cardiovascular risk categories) were randomized to 1 of 3 groups and treated once daily for 8 weeks: losartan potassium 100 mg + rosuvastatin 20 mg treatment (L/R 100/20) group, amlodipine camsylate 5 mg + losartan potassium 100 mg treatment (A/L 5/100) group, and amlodipine 5 mg + losartan potassium 100 mg + rosuvastatin 20 mg (A/L/R 5/100/20) group. The primary efficacy variables were the percent change in LDL-C in the A/L/R 5/100/20 and A/L 5/100 groups and the mean change of SiDBP in the A/L/R 5/100/20 and L/R 100/20 groups after 8 weeks of treatment, relative to baseline values. Findings A total of 146 patients were enrolled and the demographic characteristics were similar among the 3 treatment groups. After 8 weeks of treatment, the mean (SD) percent change in LDL-C was significantly greater in the A/L/R group than in the A/L group (–48.40% [2.77%] vs –6.70% [3.00%]; P < 0.0001). Moreover, the mean change in SiDBP was significantly greater in the A/L/R group than in the L/R group (–9.75 [0.92] mm Hg vs –1.73 [1.03] mm Hg; P < 0.0001). SiDBP and LDL-C reductions in the A/L/R group were comparable to reductions in the A/L and L/R groups, respectively. Ten adverse events were reported in 7 patients (4.83%), and 1 patient from the A/L group (0.69%) experienced 2 adverse drug reactions (tachycardia and face edema), which were mild and resolved without specific treatment. There were no clinically significant tolerability issues during the treatment period. Implications Triple combination therapy with amlodipine/losartan/rosuvastatin can be an effective therapeutic strategy in patients with hypertension combined with dyslipidemia. These findings will form the foundation of the future development of a single-pill triple combination. ClinicalTrials.gov identifier: NCT02899455.

KW - angiotensin receptor blocker

KW - calcium channel blocker

KW - HMG-CoA reductase inhibitor

KW - hypercholesterolemia

KW - hypertension

UR - http://www.scopus.com/inward/record.url?scp=85035090933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035090933&partnerID=8YFLogxK

U2 - 10.1016/j.clinthera.2017.10.013

DO - 10.1016/j.clinthera.2017.10.013

M3 - Article

VL - 39

SP - 2366

EP - 2379

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 12

ER -